ZURICH (Reuters) - Novartis has launched an external review into the safety of its blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns. The Swiss ...
Page Bouchard was named senior vice president and chief scientific officer of AveXis, the gene therapy unit of Novartis wrapped in a scandal over manipulated data, according to Endpoints News. Mr.
In the last year, Swiss pharma giant Novartis has spent nearly $15 billion on acquisitions that are pivoting the company toward treatments that bear little resemblance to traditional drugs, according ...
The U.S. FDA has granted Novartis' Scemblix (asciminib) Priority Review status for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. The designation is based on results from a ...
The European Medicines Agency (EMA) accepted to review Sandoz's applications for a proposed biosimilar to denosumab. The applications by Sandoz — Novartis' (NYSE:NVS) generic and biosimilars unit — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback